If the end of infusion is delayed beyond the nominal infusion duration, the collection of this sample should a lso be delayed accordingly. EOI samples may not be collected from the same IV access as the drug was administered. cSamples will be taken as directed when drug-related adverse event, Grade 3/4 infusion reaction, or hypersensitivity reaction is confirmed. Abbreviations: C = Cycle; D = Day; EOI = end of infusion; EOT = end of treatment; FU = follow-up. Revised Protocol No.: 04 Date: 31-May-2019 115 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 9.5-3: Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226 (Parts B2 and C2) Study Day of Sample Collection(1 Cycle = 4 Weeks)EventTime (Relative to Start of BMS-986226 Infusion) Hour:MinBMS-986226 Blood SampleBMS-986226 Immunogenicity Sample Treatment Cycles Cycle 1 Day 1 (C1D1)Pre-dosea00:00 X X EOIb00:30 X 04:00 X C1D2 24:00 X C1D4 72:00 X C1D8 (+/- 1 day) 168:00 X C1D15 (+/- 1 day) 336:00 X C1D22 (+/- 1 day) 504:00 X C2D1 Pre-dose 00:00 X X EOIb, 00:30 X 4:00 X C2D2 24:00 X C2D8 (+/- 1 day) 168:00 X C2D15 (+/- 1 day) 336:00 X C2D22 (+/- 1 day) 504:00 X C3D1 Pre-dose 00:00 X X EOIb00:30 X 4:00 X Revised Protocol No.: 04 Date: 31-May-2019 116 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 9.5-3: Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226 (Parts B2 and C2) Study Day of Sample Collection(1 Cycle = 4 Weeks)EventTime (Relative to Start of BMS-986226 Infusion) Hour:MinBMS-986226 Blood SampleBMS-986226 Immunogenicity Sample C3D2 24:00 X C3D8 (+/- 1 day) 168:00 X C3D15 (+/- 1 day),336:00 X C3D22 (+/- 1 day) 504:00 X C4D1 Pre-dose 00:00 X X C5D1 Pre-dose 00:00 X X C7D1 Pre-dose 00:00 X X Every 3 Cycles starting with C10D1 (example: C13D1, C16D1, etc)Pre-dose 00:00 X X Adverse Event Grade 3/4 Hypersensitivity ReactioncXX End of Treatment and Follow-up Period EOT X X 30-Day FU X X 60-Day FU X X 100-Day FU X X aAll pre-dose samples for BMS-986226 should be taken prior to the start of nivolumab/ipilimu mab infusion (preferably within 30 minutes). Revised Protocol No.: 04 Date: 31-May-2019 117 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS bThis sample should be taken immediately prior to the stopping of the second drug infu sion (in combination therapy), preferab ly within 2 minutes prior to the end of infusion. If the end of infusion is delayed beyond the nominal infusion duration, the collection of this sample should a lso be delayed accordingly.